In comparison to other antidiabetic therapies, DPP-4 inhibitors are preferable to agents associated with hypoglycemia and weight gain, though SGLT2 inhibitors exhibit superior benefits in heart failure [98]. This evidence concerns the gene SLC5A2 and heart failure.